Rhopressa Patent Expiration

Rhopressa is a drug owned by Alcon Laboratories Inc. It is protected by 14 US drug patents filed from 2018 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 14, 2034. Details of Rhopressa's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9096569 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(1 year, 11 months from now)

Active
US8450344 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(1 year, 11 months from now)

Active
US10174017 Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(5 years from now)

Active
US10654844 Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(5 years from now)

Active
US8394826 Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(6 years from now)

Active
US10588901 Combination therapy
Mar, 2034

(9 years from now)

Active
US9931336 Combination therapy
Mar, 2034

(9 years from now)

Active
US9415043 Combination therapy
Mar, 2034

(9 years from now)

Active
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10882840 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(1 year, 11 months from now)

Active
US11021456 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(1 year, 11 months from now)

Active
US10532993 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(1 year, 11 months from now)

Active
US11028081 Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(5 years from now)

Active
US11618748 Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(5 years from now)

Active
US11185538 Compositions for treating glaucoma or reducing intraocular pressure
Mar, 2034

(9 years from now)

Active


FDA has granted several exclusivities to Rhopressa. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Rhopressa, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Rhopressa.

Exclusivity Information

Rhopressa holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Rhopressa's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Rhopressa's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Rhopressa's generic, the next section provides detailed information on ongoing and past EP oppositions related to Rhopressa patents.

Rhopressa's oppositions filed in EPO

Rhopressa has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 13, 2021, by Alfred E. Tiefenbacher (Gmbh & Co. Kg). This opposition was filed on patent number EP18206195A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP18206195A Aug, 2021 Isarpatent - Patent- und Rechtsanwälte Barth Charles Hassa Peckmann und Partner mbB Granted and Under Opposition
EP18206195A Aug, 2021 df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB Granted and Under Opposition
EP18206195A Aug, 2021 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition


US patents provide insights into the exclusivity only within the United States, but Rhopressa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rhopressa's family patents as well as insights into ongoing legal events on those patents.

Rhopressa's family patents

Rhopressa has patent protection in a total of 12 countries. It's US patent count contributes only to 43.2% of its total global patent coverage. Click below to unlock the full patent family tree for Rhopressa.

Family Patents

Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Rhopressa's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 14, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Rhopressa Generics:

There are no approved generic versions for Rhopressa as of now.

How can I launch a generic of Rhopressa before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Rhopressa's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Rhopressa's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Rhopressa -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.0002 20 Dec, 2021 2 14 Mar, 2034




About Rhopressa

Rhopressa is a drug owned by Alcon Laboratories Inc. It is used for lowering elevated intraocular pressure. Rhopressa uses Netarsudil Mesylate as an active ingredient. Rhopressa was launched by Alcon Labs Inc in 2017.

Market Authorisation Date:

Rhopressa was approved by FDA for market use on 18 December, 2017.

NCE-1 date:

NCE-1 date is also known as the four year date as it is four years after the original drug approval. Since the approval date for Rhopressa is 18 December, 2017, its NCE-1 date is estimated to be 18 December, 2021

Active Ingredient:

Rhopressa uses Netarsudil Mesylate as the active ingredient. Check out other Drugs and Companies using Netarsudil Mesylate ingredient

Treatment:

Rhopressa is used for lowering elevated intraocular pressure.

Dosage:

Rhopressa is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.02% BASE SOLUTION/DROPS Prescription OPHTHALMIC